

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Buckingham, et al.

August 24, 2001

Serial No.:

Not Assigned

Group Art Unit No.: Not Assigned

Filed:

Herewith

Attorney Docket No. P31853C1

Examiner: Not Assigned

For:

TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE,

INSULIN SECRETAGOGUE AND DIGUANIDE

PRELIMINARY AMENDMENT

Preliminary to the examination of this application, Applicants respectfully request amendment of the above-identified application as follows:

In the Specification:

Kindly add the Abstract enclosed herewith on a separate sheet, at the end.

In the Claims:

Please amend claims 4-12, 16, 18-20 and 22 as follows:

- 4. (Amended) A method according to claim 1, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4dione (Compound I).
- 5. (Amended) A method according to claim 4, which comprises the administration of 2 to 12 mg of Compound (I).
- 6. (Amended) A method according for claim 5, which comprises the administration of 2 to 4, 4 to 8 or 8 to 12/mg of Compound (I).
- 7. (Amended) A method according to claim 6, which comprises the administration of 2 to 4mg of Compound (I).
- 8. (Amended) A method according to claim 6, which comprises the method the administration of 4 to 8mg of Compound (I).

